Gilead Sciences, Inc. (GILD) stock
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Earnings
Gilead Sciences's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Feb 9, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$8.30B
+6.4% on a year earlier
Non-GAAP diluted EPS, Q3 FY2026
$2.55
$2.47 a year earlier
Latest guidance
Lowered
Oct 29, 2026 · 5 items
Quarterly results
Revenue and earnings per share from each of Gilead Sciences's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 9, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Oct 29, 2026after the close | $8.30B | +6.4% | $1.94 | $2.55 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 4, 2026after the close | $7.80B | +9.9% | -$8.45 | -$6.75 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026after the close | $6.96B | +3.9% | $1.61 | $2.03 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 10, 2026after the close | $7.90B | +3.9% | $1.74 | $1.86 | Release |
| Q3 FY2025ended Sep 30, 2025 | Oct 30, 2025after the close | $7.80B | +4.0% | $2.43 | $2.47 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025after the close | $7.10B | +1.4% | $1.56 | $2.01 | Release |
| Q1 FY2025ended Mar 31, 2025 | Apr 24, 2025after the close | $6.70B | 0.0% | $1.04 | $1.81 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 11, 2025after the close | $7.60B | +7.0% | $1.42 | $1.90 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 6, 2024after the close | $7.50B | +5.6% | $1.00 | $2.02 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 8, 2024after the close | $7.00B | +6.1% | $1.29 | $2.01 | Release |
| Q1 FY2024ended Mar 31, 2024 | Apr 25, 2024after the close | $6.70B | +4.7% | -$3.34 | -$1.32 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 6, 2024after the close | $7.10B | -4.1% | $1.14 | $1.72 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 7, 2023after the close | $7.10B | +1.4% | $1.73 | $2.29 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 3, 2023after the close | $6.60B | +4.8% | $0.83 | $1.34 | Release |
| Q1 FY2023ended Mar 31, 2023 | Apr 27, 2023after the close | $6.40B | -3.0% | $0.80 | $1.37 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 2, 2023after the close | $7.40B | +2.8% | $1.30 | $1.67 | Release |
| Q3 FY2022ended Sep 30, 2022 | Oct 27, 2022after the close | $7.00B | -5.4% | $1.42 | $1.90 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 2, 2022after the close | $6.30B | – | $0.91 | $1.58 | Release |
| Q1 FY2022ended Mar 31, 2022 | Apr 28, 2022after the close | $6.60B | – | $0.02 | $2.12 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 1, 2022after the close | $7.20B | – | $0.30 | $0.69 | Release |
| Q3 FY2021ended Sep 30, 2021 | Oct 28, 2021after the close | $7.40B | – | $2.05 | $2.65 | Release |
| Q2 FY2021ended Jun 30, 2021 | Jul 29, 2021after the close | – | – | – | – | Release |
| Q1 FY2021ended Mar 31, 2021 | Apr 29, 2021after the close | – | – | – | – | Release |
| Q4 FY2020ended Dec 31, 2020 | Feb 4, 2021after the close | – | – | – | – | Release |
| Q3 FY2020ended Sep 30, 2020 | Oct 28, 2020after the close | – | – | – | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Gilead Sciences's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Product sales | FY2026 | $31.00B – $31.30B | – | New | Oct 29, 2026 |
| Product salesGAAP | FY2026 | $30.10B – $30.40B | – | New | Aug 4, 2026 |
| Product sales | FY2026 | $30.00B – $30.40B | $29.60B – $30.00B | Raised | May 7, 2026 |
| GAAP projected product gross marginGAAP | FY2026 | 79% | 79% | Reaffirmed | Aug 4, 2026 |
| Non-GAAP projected product gross marginnon-GAAP | FY2026 | 87% | 87% | Reaffirmed | Aug 4, 2026 |
| GAAP projected operating income (loss)GAAP | FY2026 | -$2.25B – -$1.85B | -$1.00B – -$500.00M | Lowered | Aug 4, 2026 |
| Non-GAAP projected operating incomenon-GAAP | FY2026 | $2.90B – $3.30B | $2.40B – $2.90B | Raised | Aug 4, 2026 |
| Diluted loss per shareGAAP | FY2026 | -$4.40 – -$4.05 | – | New | Oct 29, 2026 |
| Diluted loss per shareGAAP | FY2026 | -$3.75 – -$3.40 | -$3.25 – -$2.85 | Lowered | Aug 4, 2026 |
| Non-GAAP diluted loss per sharenon-GAAP | FY2026 | -$1.20 – -$0.85 | – | New | Oct 29, 2026 |
| Non-GAAP diluted loss per sharenon-GAAP | FY2026 | -$0.65 – -$0.30 | -$1.05 – -$0.65 | Raised | Aug 4, 2026 |
| GAAP projected effective tax rateGAAP | FY2026 | -90% – -80% | -220% – -150% | Raised | Aug 4, 2026 |
| Non-GAAP projected effective tax ratenon-GAAP | FY2026 | 115% – 140% | 140% – 190% | Lowered | Aug 4, 2026 |
| Product sales excluding Veklury | FY2026 | $30.70B – $31.00B | – | New | Oct 29, 2026 |
| Veklury | FY2026 | $300.00M | – | Lowered | Oct 29, 2026 |
Guidance vs results
The last range Gilead Sciences gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | EPS (GAAP) | $6.65 – $6.85 | $6.77Σ4Q | Within range |
| FY2025 | Non-GAAP diluted EPS | $8.05 – $8.25 | $8.15Σ4Q | Within range |
| FY2025 | Revenue | $28.40B – $28.70B | $29.50BΣ4Q | Above range |
Guidance history
Every forecast Gilead Sciences put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Oct 29, 2026 | Non-GAAP diluted loss per share | FY2026 | -$1.20 – -$0.85 | New |
| Oct 29, 2026 | Diluted loss per share | FY2026 | -$4.40 – -$4.05 | New |
| Oct 29, 2026 | Product sales excluding Veklury | FY2026 | $30.70B – $31.00B | New |
| Oct 29, 2026 | Veklury | FY2026 | $300.00M | Lowered |
| Oct 29, 2026 | Product sales | FY2026 | $31.00B – $31.30B | New |
| Aug 4, 2026 | Non-GAAP diluted loss per share | FY2026 | -$0.65 – -$0.30 | Raised |
| Aug 4, 2026 | Diluted loss per share | FY2026 | -$3.75 – -$3.40 | Lowered |
| Aug 4, 2026 | GAAP projected product gross margin | FY2026 | 79% | Reaffirmed |
| Aug 4, 2026 | Non-GAAP projected product gross margin | FY2026 | 87% | Reaffirmed |
| Aug 4, 2026 | GAAP projected operating income (loss) | FY2026 | -$2.25B – -$1.85B | Lowered |
| Aug 4, 2026 | Non-GAAP projected operating income | FY2026 | $2.90B – $3.30B | Raised |
| Aug 4, 2026 | GAAP projected effective tax rate | FY2026 | -90% – -80% | Raised |
| Aug 4, 2026 | Non-GAAP projected effective tax rate | FY2026 | 115% – 140% | Lowered |
| Aug 4, 2026 | Product sales | FY2026 | $30.10B – $30.40B | New |
| Aug 4, 2026 | Product sales excluding Veklury | FY2026 | $29.80B – $30.10B | Lowered |
| Aug 4, 2026 | Veklury | FY2026 | $300.00M | Lowered |
| May 7, 2026 | Non-GAAP diluted (loss) earnings per share | FY2026 | -$1.05 – -$0.65 | Lowered |
| May 7, 2026 | Diluted (loss) earnings per share | FY2026 | -$3.25 – -$2.85 | Lowered |
| May 7, 2026 | Non-GAAP projected product gross margin | FY2026 | 87% | Reaffirmed |
| May 7, 2026 | GAAP projected product gross margin | FY2026 | 79% | Reaffirmed |
| May 7, 2026 | GAAP projected operating income (loss) | FY2026 | -$1.00B – -$500.00M | Lowered |
| May 7, 2026 | Non-GAAP projected operating income | FY2026 | $2.40B – $2.90B | Lowered |
| May 7, 2026 | GAAP projected effective tax rate | FY2026 | -220% – -150% | Lowered |
| May 7, 2026 | Non-GAAP projected effective tax rate | FY2026 | 140% – 190% | Raised |
| May 7, 2026 | Product sales | FY2026 | $30.00B – $30.40B | Raised |
| May 7, 2026 | Product sales excluding Veklury | FY2026 | $29.40B – $29.80B | Lowered |
| May 7, 2026 | Veklury | FY2026 | $600.00M | Lowered |
| Feb 10, 2026 | Non-GAAP diluted EPS | FY2026 | $8.45 – $8.85 | New |
| Feb 10, 2026 | Diluted EPS | FY2026 | $6.75 – $7.15 | New |
| Feb 10, 2026 | GAAP projected product gross margin | FY2026 | 79% | New |
| Feb 10, 2026 | Non-GAAP projected product gross margin | FY2026 | 87% | New |
| Feb 10, 2026 | GAAP projected operating income | FY2026 | $11.40B – $11.90B | New |
| Feb 10, 2026 | Non-GAAP projected operating income | FY2026 | $13.80B – $14.30B | New |
| Feb 10, 2026 | GAAP projected effective tax rate | FY2026 | 21% | New |
| Feb 10, 2026 | Non-GAAP projected effective tax rate | FY2026 | 20% | New |
| Feb 10, 2026 | Product sales | FY2026 | $29.60B – $30.00B | New |
| Feb 10, 2026 | Product sales excluding Veklury | FY2026 | $29.00B – $29.40B | Lowered |
| Feb 10, 2026 | Veklury | FY2026 | $600.00M | Lowered |
| Oct 30, 2025 | Non-GAAP diluted EPS | FY2025 | $8.05 – $8.25 | Raised |
| Oct 30, 2025 | Diluted EPS | FY2025 | $6.65 – $6.85 | Raised |
| Oct 30, 2025 | GAAP projected product gross margin | FY2025 | 78% | Reaffirmed |
| Oct 30, 2025 | Non-GAAP projected product gross margin | FY2025 | 86% | Reaffirmed |
| Oct 30, 2025 | GAAP projected operating income | FY2025 | $10.30B – $10.60B | Lowered |
| Oct 30, 2025 | Non-GAAP projected operating income | FY2025 | $13.10B – $13.40B | Raised |
| Oct 30, 2025 | GAAP projected effective tax rate | FY2025 | 16% | Lowered |
| Oct 30, 2025 | Non-GAAP projected effective tax rate | FY2025 | 19% | Reaffirmed |
| Oct 30, 2025 | Product sales | FY2025 | $28.40B – $28.70B | Raised |
| Oct 30, 2025 | Product sales excluding Veklury | FY2025 | $27.40B – $27.70B | Lowered |
| Oct 30, 2025 | Veklury | FY2025 | $1.00B | Lowered |
| Aug 7, 2025 | Non-GAAP diluted EPS | FY2025 | $7.95 – $8.25 | New |
| Aug 7, 2025 | Diluted EPS | FY2025 | $5.85 – $6.15 | New |
| Aug 7, 2025 | GAAP projected product gross margin | FY2025 | 78% | New |
| Aug 7, 2025 | Non-GAAP projected product gross margin | FY2025 | 86% | New |
| Aug 7, 2025 | GAAP projected operating income | FY2025 | $10.30B – $10.70B | New |
| Aug 7, 2025 | Non-GAAP projected operating income | FY2025 | $13.00B – $13.40B | New |
| Aug 7, 2025 | GAAP projected effective tax rate | FY2025 | 21% | New |
| Aug 7, 2025 | Non-GAAP projected effective tax rate | FY2025 | 19% | New |
| Aug 7, 2025 | Product sales | FY2025 | $28.30B – $28.70B | New |
| Aug 7, 2025 | Product sales excluding Veklury | FY2025 | $27.30B – $27.70B | Lowered |
| Aug 7, 2025 | Veklury | FY2025 | $1.00B | Lowered |
| Apr 24, 2025 | Non-GAAP diluted EPS | FY2025 | $7.70 – $8.10 | Reaffirmed |
| Apr 24, 2025 | Diluted EPS | FY2025 | $5.65 – $6.05 | Lowered |
| Apr 24, 2025 | GAAP projected product gross margin | FY2025 | 77% – 78% | Reaffirmed |
| Apr 24, 2025 | Non-GAAP projected product gross margin | FY2025 | 85% – 86% | Reaffirmed |
| Apr 24, 2025 | GAAP projected operating income | FY2025 | $10.20B – $10.70B | Reaffirmed |
| Apr 24, 2025 | Non-GAAP projected operating income | FY2025 | $12.70B – $13.20B | Reaffirmed |
| Apr 24, 2025 | GAAP projected effective tax rate | FY2025 | 21% | Raised |
| Apr 24, 2025 | Non-GAAP projected effective tax rate | FY2025 | 19% | Reaffirmed |
| Apr 24, 2025 | Product sales excluding Veklury | FY2025 | $26.80B – $27.20B | New |
| Apr 24, 2025 | Veklury | FY2025 | $1.40B | Lowered |
| Apr 24, 2025 | Product sales | FY2025 | $28.20B – $28.60B | Raised |
| Feb 11, 2025 | Non-GAAP diluted EPS | FY2025 | $7.70 – $8.10 | New |
| Feb 11, 2025 | Diluted EPS | FY2025 | $5.95 – $6.35 | New |
| Feb 11, 2025 | GAAP projected product gross margin | FY2025 | 77% – 78% | New |
| Feb 11, 2025 | Non-GAAP projected product gross margin | FY2025 | 85% – 86% | New |
| Feb 11, 2025 | GAAP projected operating income | FY2025 | $10.20B – $10.70B | New |
| Feb 11, 2025 | Non-GAAP projected operating income | FY2025 | $12.70B – $13.20B | New |
| Feb 11, 2025 | GAAP projected effective tax rate | FY2025 | 20% | New |
| Feb 11, 2025 | Non-GAAP projected effective tax rate | FY2025 | 19% | New |
| Feb 11, 2025 | Product sales excluding Veklury | FY2025 | $26.80B – $27.20B | Lowered |
| Feb 11, 2025 | Product sales | FY2025 | $28.20B – $28.60B | New |
| Feb 11, 2025 | Veklury | FY2025 | $1.40B | Lowered |
| Nov 6, 2024 | Non-GAAP diluted EPS | FY2024 | $4.25 – $4.45 | Raised |
| Nov 6, 2024 | Diluted EPS | FY2024 | $0.05 – $0.25 | Narrowed |
| Nov 6, 2024 | Product sales | FY2024 | $27.80B – $28.10B | Raised |
| Nov 6, 2024 | Product sales, excluding Veklury | FY2024 | $26.00B – $26.30B | Lowered |
| Nov 6, 2024 | Veklury | FY2024 | $1.80B | Lowered |
| Aug 8, 2024 | Non-GAAP diluted EPS | FY2024 | $3.60 – $3.90 | Raised |
| Aug 8, 2024 | Diluted EPS | FY2024 | $0.00 – $0.30 | Lowered |
| Aug 8, 2024 | Non-GAAP projected product gross margin | FY2024 | 85% – 86% | Reaffirmed |
| Aug 8, 2024 | GAAP projected product gross margin | FY2024 | 76% – 77% | Reaffirmed |
| Aug 8, 2024 | GAAP projected operating income | FY2024 | $2.10B – $2.50B | Raised |
| Aug 8, 2024 | Non-GAAP projected operating income | FY2024 | $7.20B – $7.60B | Raised |
| Aug 8, 2024 | GAAP projected effective tax rate | FY2024 | 87% | Raised |
| Aug 8, 2024 | Non-GAAP projected effective tax rate | FY2024 | 30% | Reaffirmed |
| Aug 8, 2024 | Product sales, excluding Veklury | FY2024 | $25.80B – $26.20B | Raised |
| Aug 8, 2024 | Veklury | FY2024 | $1.30B | Lowered |
| Aug 8, 2024 | Product sales | FY2024 | $27.10B – $27.50B | Reaffirmed |
| Apr 25, 2024 | Non-GAAP diluted EPS | FY2024 | $3.45 – $3.85 | Lowered |
| Apr 25, 2024 | Diluted EPS | FY2024 | $0.10 – $0.50 | Lowered |
| Apr 25, 2024 | GAAP projected product gross margin | FY2024 | 76% – 77% | Reaffirmed |
| Apr 25, 2024 | Non-GAAP projected product gross margin | FY2024 | 85% – 86% | Reaffirmed |
| Apr 25, 2024 | GAAP projected operating income | FY2024 | $1.90B – $2.40B | Lowered |
| Apr 25, 2024 | Non-GAAP projected operating income | FY2024 | $7.00B – $7.50B | Lowered |
| Apr 25, 2024 | Product sales, excluding Veklury | FY2024 | $25.80B – $26.20B | Raised |
| Apr 25, 2024 | Non-GAAP projected effective tax rate | FY2024 | 30% | Raised |
| Apr 25, 2024 | GAAP projected effective tax rate | FY2024 | 65% | Raised |
| Apr 25, 2024 | Veklury | FY2024 | $1.30B | Lowered |
| Apr 25, 2024 | Product sales | FY2024 | $27.10B – $27.50B | Reaffirmed |
| Feb 6, 2024 | Non-GAAP diluted EPS | FY2024 | $6.85 – $7.25 | New |
| Feb 6, 2024 | Diluted EPS | FY2024 | $5.15 – $5.55 | New |
| Feb 6, 2024 | GAAP projected product gross margin | FY2024 | 76% – 77% | New |
| Feb 6, 2024 | Non-GAAP projected product gross margin | FY2024 | 85% – 86% | New |
| Feb 6, 2024 | GAAP projected operating income | FY2024 | $8.70B – $9.20B | New |
| Feb 6, 2024 | Non-GAAP projected operating income | FY2024 | $11.20B – $11.70B | New |
| Feb 6, 2024 | GAAP projected effective tax rate | FY2024 | 21% | New |
| Feb 6, 2024 | Non-GAAP projected effective tax rate | FY2024 | 19% | New |
| Feb 6, 2024 | Total product sales, excluding Veklury | FY2024 | $25.80B – $26.20B | New |
| Feb 6, 2024 | Total Veklury sales | FY2024 | $1.30B | Lowered |
| Feb 6, 2024 | Total product sales | FY2024 | $27.10B – $27.50B | New |
| Nov 7, 2023 | Non-GAAP diluted earnings per share | FY2023 | $6.65 – $6.85 | Raised |
| Nov 7, 2023 | Diluted earnings per share | FY2023 | $4.55 – $4.75 | Narrowed |
| Nov 7, 2023 | Total product sales, excluding Veklury | FY2023 | $24.80B – $25.00B | Raised |
| Nov 7, 2023 | Total Veklury sales | FY2023 | $1.90B | Lowered |
| Nov 7, 2023 | Total product sales | FY2023 | $26.70B – $26.90B | Raised |
| Aug 3, 2023 | Non-GAAP diluted earnings per share | FY2023 | $6.45 – $6.80 | Lowered |
| Aug 3, 2023 | Diluted earnings per share | FY2023 | $4.50 – $4.85 | Lowered |
| Aug 3, 2023 | Total Veklury sales | FY2023 | $1.70B | Lowered |
| Aug 3, 2023 | Total product sales, excluding Veklury | FY2023 | $24.60B – $25.00B | New |
| Aug 3, 2023 | Total product sales | FY2023 | $26.30B – $26.70B | Raised |
| Apr 27, 2023 | Non-GAAP diluted earnings per share | FY2023 | $6.60 – $7.00 | Reaffirmed |
| Apr 27, 2023 | Diluted earnings per share | FY2023 | $4.75 – $5.15 | Lowered |
| Apr 27, 2023 | Total product sales, excluding Veklury | FY2023 | $24.00B – $24.50B | Raised |
| Apr 27, 2023 | Total Veklury sales | FY2023 | $2.00B | Lowered |
| Apr 27, 2023 | Total product sales | FY2023 | $26.00B – $26.50B | Reaffirmed |
| Feb 2, 2023 | Non-GAAP earnings per share | FY2023 | $6.60 – $7.00 | New |
| Feb 2, 2023 | Earnings per share | FY2023 | $5.30 – $5.70 | New |
| Feb 2, 2023 | GAAP projected product gross margin | FY2023 | 79% | New |
| Feb 2, 2023 | Non-GAAP projected product gross margin | FY2023 | 86% | New |
| Feb 2, 2023 | GAAP projected operating income | FY2023 | $9.20B – $9.80B | New |
| Feb 2, 2023 | Non-GAAP projected operating income | FY2023 | $11.00B – $11.60B | New |
| Feb 2, 2023 | GAAP projected effective tax rate | FY2023 | 22% | New |
| Feb 2, 2023 | Non-GAAP projected effective tax rate | FY2023 | 20% | New |
| Feb 2, 2023 | Total product sales, excluding Veklury | FY2023 | $24.00B – $24.50B | New |
| Feb 2, 2023 | Total Veklury sales | FY2023 | $2.00B | Lowered |
| Feb 2, 2023 | Total product sales | FY2023 | $26.00B – $26.50B | New |
| Oct 27, 2022 | Non-GAAP earnings per share | FY2022 | $6.95 – $7.15 | Raised |
| Oct 27, 2022 | Earnings per share | FY2022 | $3.35 – $3.55 | Raised |
| Oct 27, 2022 | Total product sales, excluding Veklury | FY2022 | $22.50B – $22.80B | Raised |
| Oct 27, 2022 | Total Veklury sales | FY2022 | $3.40B | Lowered |
| Oct 27, 2022 | Total product sales | FY2022 | $25.90B – $26.20B | Raised |
| Aug 2, 2022 | Non-GAAP earnings per share | FY2022 | $6.35 – $6.75 | Raised |
| Aug 2, 2022 | Earnings per share | FY2022 | $2.90 – $3.30 | Lowered |
| Aug 2, 2022 | GAAP projected product gross margin | FY2022 | 76% – 77% | New |
| Aug 2, 2022 | Non-GAAP projected product gross margin | FY2022 | 85% – 86% | New |
| Aug 2, 2022 | GAAP projected income from operations | FY2022 | $6.05B – $6.65B | New |
| Aug 2, 2022 | Non-GAAP projected income from operations | FY2022 | $11.00B – $11.60B | New |
| Aug 2, 2022 | GAAP projected effective tax rate | FY2022 | 21% | New |
| Aug 2, 2022 | Non-GAAP projected effective tax rate | FY2022 | 20% | New |
| Aug 2, 2022 | Total Veklury sales | FY2022 | $2.50B | Raised |
| Aug 2, 2022 | Total product sales, excluding Veklury | FY2022 | $22.00B – $22.50B | New |
| Aug 2, 2022 | Total product sales | FY2022 | $24.50B – $25.00B | Raised |
| Apr 28, 2022 | Non-GAAP earnings per share | FY2022 | $6.20 – $6.70 | Reaffirmed |
| Apr 28, 2022 | EPS | FY2022 | $3.00 – $3.50 | Lowered |
| Apr 28, 2022 | Total product sales | FY2022 | $23.80B – $24.30B | Reaffirmed |
| Feb 1, 2022 | Non-GAAP earnings per share | FY2022 | $6.20 – $6.70 | New |
| Feb 1, 2022 | Earnings per share | FY2022 | $4.70 – $5.20 | New |
| Feb 1, 2022 | Total product sales, excluding Veklury | FY2022 | $21.80B – $22.30B | New |
| Feb 1, 2022 | Total Veklury sales | FY2022 | $2.00B | Lowered |
| Feb 1, 2022 | Total product sales | FY2022 | $23.80B – $24.30B | New |
| Oct 28, 2021 | Non-GAAP earnings per share | FY2021 | $7.90 – $8.10 | New |
| Oct 28, 2021 | GAAP earnings per share | FY2021 | $5.50 – $5.70 | New |
| Oct 28, 2021 | Total Veklury sales | FY2021 | $4.50B – $4.80B | New |
| Oct 28, 2021 | Total product sales | FY2021 | $26.00B – $26.30B | New |
| Oct 28, 2021 | Total product sales, excluding Veklury | FY2021 | $21.50B | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Gilead Sciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Update
- Update
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Update
- News